{
    "clinical_study": {
        "@rank": "132663", 
        "arm_group": [
            {
                "arm_group_label": "Melatonin", 
                "arm_group_type": "Active Comparator", 
                "description": "Melatonin, Tablet, 3 mg, once, one month"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo, tablet"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study was to evaluate the efficacy and safety of Melatonin in treatment\n      of fatigue and Quality of Life of MS patients."
        }, 
        "brief_title": "Effect of Melatonin on Multiple Sclerosis Related Fatigue", 
        "completion_date": {
            "#text": "October 2012", 
            "@type": "Actual"
        }, 
        "condition": "Fatigue", 
        "condition_browse": {
            "mesh_term": [
                "Fatigue", 
                "Multiple Sclerosis", 
                "Sclerosis"
            ]
        }, 
        "detailed_description": {
            "textblock": "Multiple Sclerosis (MS) is one of the most common non-traumatic causes of disability in the\n      world. It is a chronic inflammatory and demyelinating disorder of the Central Nervous System\n      (CNS) which affects individuals in the productive ages and causes a large burden for years\n      to come. Fatigue is a common complaint and one of the least understood symptoms of MS"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. definite diagnosis of relapsing-remitting MS (RRMS) by the MacDonald criteria\n\n          2. a baseline of Expanded Disability Status Score (EDSS)of less than 5.0\n\n          3. aged between 18 and 55 years of either sex\n\n          4. treated with one type of interferon beta-1a (IFNB-1a);\n\n          5. signed an informed consent\n\n        Exclusion Criteria:\n\n          1. clinical relapsing of MS during past 30 days;\n\n          2. use of melatonin and warfarin within 30 days prior to participation;\n\n          3. concomitant use of beta-blockers, anti-diabetic agents, antiplatelet agents, NSAIDS,\n             aspirin ;\n\n          4. working more than one nighttime shift per month;\n\n          5. Pregnancy or lactation;\n\n          6. history of a chronic hematological, cardiac, hepatic, renal or thyroid disorders ;\n\n          7. failure to adhere  to the study protocol"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "44", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 28, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01718678", 
            "org_study_id": "ASD-12111"
        }, 
        "intervention": [
            {
                "arm_group_label": "Melatonin", 
                "description": "it is kind of drug", 
                "intervention_name": "Melatonin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "It is Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Melatonin"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Multiple sclerosis", 
            "Melatonin", 
            "Fatigue", 
            "Quality of life"
        ], 
        "lastchanged_date": "October 30, 2012", 
        "link": {
            "description": "Isfahan university of medical sciences", 
            "url": "http://www.mui.ac.ir"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Isfahan", 
                    "country": "Iran, Islamic Republic of", 
                    "zip": "7007"
                }, 
                "name": "Al-zahra university hospital"
            }
        }, 
        "location_countries": {
            "country": "Iran, Islamic Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "Study of Melatonin in Treatment of Fatigue in Multiple Sclerosis", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Iran: Ministry of Health", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "October 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Modified Fatigue Impact Scale (MFIS)is a21-item (score range of each item: 0-4) questionnaire with the total score computed from 0 (no impact of fatigue) to 84 (maximum impact of fatigue) in three subscales containing: physical (9 items), cognitive (10 items) and psychosocial (2 items) aspects.", 
            "measure": "Fatigue", 
            "safety_issue": "Yes", 
            "time_frame": "at one month after treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01718678"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Isfahan University of Medical Sciences", 
            "investigator_full_name": "Hamidreza Shemshaki", 
            "investigator_title": "research assistant", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Quality Of Life Questionnaire (MSQOL-54) consisted of 54 questions (items), each one, assigned to a score ranging from 0 to 100.", 
            "measure": "Quality Of Life", 
            "safety_issue": "Yes", 
            "time_frame": "at one month after treatment"
        }, 
        "source": "Isfahan University of Medical Sciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Isfahan University of Medical Sciences", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2012"
    }
}